Related Experiment Video
Updated: May 7, 2026
12:04
The bm12 Inducible Model of Systemic Lupus Erythematosus (SLE) in C57BL/6 Mice
Published on: November 1, 2015
E2F1: a potential therapeutic target for systematic lupus erythematosus
1Department of Epidemiology and Biostatistics, Anhui Medical University, Hefei, Anhui, 230032, People's Republic of China.
Rheumatology International
|September 28, 2013
Summary
Targeting the E2F1 protein, a key regulator of cell cycle and apoptosis, may offer novel therapeutic strategies for systemic lupus erythematosus (SLE). This approach addresses immune dysfunction in SLE by modulating T cell and dendritic cell function.
Area of Science:
- Immunology
- Molecular Biology
- Genetics
Background:
- E2F1 is a transcriptional activator regulating genes essential for cell cycle progression.
- E2F1 plays a critical role in the apoptosis of dendritic cells (DC) and T cells.
Discussion:
- Systemic lupus erythematosus (SLE) pathogenesis involves significant immune dysfunction, particularly impaired regulatory T cell and DC function.
- E2F1's role in immune cell apoptosis suggests its involvement in SLE pathogenesis.
Key Insights:
- E2F1 acts as a crucial regulator in immune cell apoptosis.
- Dysfunctional immune cells, including regulatory T cells and DCs, are implicated in SLE.
Outlook:
- Therapeutic strategies targeting E2F1 present a promising avenue for innovative SLE treatments.
- Modulating E2F1 could restore immune homeostasis and offer a new therapeutic paradigm for SLE.
Related Concept Videos
01:11Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
02:26NF-κB-dependent Signaling Pathway
The transcription factor NF-κB was discovered in 1986 in the lab of Nobel laureate Professor David Baltimore, for its interaction with the immunoglobulin light chain enhancer in B-cells. After more than three decades of study, it is now evident that NF-κB regulates the expression of over 100 genes. Most of these genes play an essential role in the innate and adaptive immune responses as well as the inflammatory responses of animals.
NF-κB-dependent Signaling Mechanism
The heterodimer of NF-κB...
NF-κB-dependent Signaling Mechanism
The heterodimer of NF-κB...